We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-19.38%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$264M
AUM Growth
-$174M
(-40%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-39.14%
Top 10 Holdings %
Top 10 Hldgs %
67.94%
Holding
42
New
13
Increased
4
Reduced
13
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$21.5M |
| 2 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$12.2M |
| 3 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$9.79M |
| 4 |
Viatris
VTRS
|
+$8.62M |
| 5 |
Quest Diagnostics
DGX
|
+$7.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bio-Rad Laboratories Class A
BIO
|
+$22.1M |
| 2 |
Zimmer Biomet
ZBH
|
+$18.6M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$18.6M |
| 4 |
Johnson & Johnson
JNJ
|
+$18M |
| 5 |
Medtronic
MDT
|
+$17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.22% |
| 2 | Technology | 6.62% |
| 3 | Financials | 0.53% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Quest Diagnostics
DGX
$25.7B
| $25.5M | 9.64% |
317,000
+72,000
| +29% | +$7.45M |
|
|
2
Medtronic
MDT
$109B
| $20.3M | 7.68% |
225,000
-160,000
| -42% | -$17M |
|
3
AtriCure
ATRC
$1.92B
| $20.2M | 7.63% |
600,000
-260,000
| -30% | -$9.35M |
|
|
MDRX
4
DELISTED
Veradigm Inc. Common Stock
MDRX
| $19.8M | 7.49% |
2,810,000
-840,000
| -23% | -$6.82M |
|
|
5
Perrigo
PRGO
$1.4B
| $19.2M | 7.28% |
+400,000
| New | +$21.5M |
|
6
Pacira BioSciences
PCRX
$1.04B
| $18.4M | 6.98% |
550,000
-72,500
| -12% | -$3.01M |
|
7
United Therapeutics
UTHR
$25.8B
| $15.3M | 5.78% |
161,000
+9,600
| +6% | +$912K |
|
|
8
Bio-Rad Laboratories Class A
BIO
$8.71B
| $14M | 5.31% |
40,000
-60,000
| -60% | -$22.1M |
|
|
9
Viatris
VTRS
$20.4B
| $13.4M | 5.08% |
900,000
+450,000
| +100% | +$8.62M |
|
|
HOLX
10
DELISTED
Hologic
HOLX
| $13.3M | 5.05% |
380,000
-95,000
| -20% | -$4.52M |
|
|
NUAN
11
DELISTED
Nuance Communications, Inc.
NUAN
| $10.5M | 3.97% |
+625,000
| New | +$12.2M |
|
12
Rigel Pharmaceuticals
RIGL
$681M
| $8.66M | 3.28% |
555,000
-20,000
| -3% | -$426K |
|
|
CHNG
13
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $6.99M | 2.65% |
+700,000
| New | +$9.79M |
|
|
OPTN
14
DELISTED
OptiNose
OPTN
| $6.96M | 2.64% |
103,333
+33,333
| +48% | +$3.36M |
|
15
Merck
MRK
$322B
| $6.92M | 2.62% |
+94,320
| New | +$7.41M |
|
16
Phreesia
PHR
$663M
| $5.26M | 1.99% |
250,000
-410,000
| -62% | -$11.2M |
|
17
CALL
SPDR Gold Trust
GLD
$131B
| $4.3M | 1.63% |
+3,500
| New | +$521K |
|
|
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.3M | 1.63% |
1,250,000
-1,400,000
| -53% | -$8.18M |
|
|
PGNX
19
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $4.18M | 1.58% |
+1,100,000
| New | +$4.74M |
|
|
STRM
20
DELISTED
Streamline Health Solutions
STRM
| $3.66M | 1.39% |
287,059
| – | – |
|
21
Becton Dickinson
BDX
$45.6B
| $3.45M | 1.31% |
+15,375
| New | +$3.8M |
|
22
Pfizer
PFE
$143B
| $3.26M | 1.24% |
+105,400
| New | +$3.59M |
|
23
Lantheus
LNTH
$6.49B
| $2.55M | 0.97% |
200,000
-450,000
| -69% | -$7.19M |
|
24
SI-BONE Inc
SIBN
$788M
| $2.47M | 0.94% |
+207,000
| New | +$3.8M |
|
25
RadNet
RDNT
$5.02B
| $2.37M | 0.9% |
225,000
-175,000
| -44% | -$3.3M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q1 2020 Portfolio in Review
As of Q1 2020, Tamarack Advisers held 42 positions worth $264M, down 40% from $438M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers withdrew a net $103M in Q1 2020, closing 11 positions and reducing 13 holdings. Its most notable exit was Zimmer Biomet, an estimated $18.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology and Financials.
Against the trend, Tamarack Advisers opened a new position in Perrigo worth $19.2M.
- Tamarack Advisers's largest Q1 2020 buy was Perrigo: 400,000 shares worth $19.2M.
- Tamarack Advisers added most to Viatris in Q1 2020, an estimated $8.62M increase.
- Tamarack Advisers's biggest Q1 2020 reduction was Bio-Rad Laboratories Class A, cutting an estimated $22.1M.
- Tamarack Advisers fully exited Zimmer Biomet in Q1 2020, selling an estimated $18.6M.
- Tamarack Advisers's ten largest holdings make up 68% of its $264M portfolio in Q1 2020.
- Tamarack Advisers opened 13 new positions and closed 11 in Q1 2020.
- Tamarack Advisers's portfolio value fell 40% quarter-over-quarter to $264M.
Based on Tamarack Advisers's 13F filing for Q1 2020, filed 14 May 2020.